Advertisement
Product › Details
Kyprolis®
Next higher product group | carfilzomib | |
Status | 2013-08-25 registration existent | |
Organisation | Onyx Pharmaceuticals Inc. | |
Group | Amgen (Group) | |
Organisation 2 | Proteolix Inc. | |
Today | Onyx Pharmaceuticals Inc. | |
Group | Amgen (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for cancer drug
- [1] Theolytics Ltd.. (4/17/24). "Press Release: Theolytics Successfully Closes Latest Financing Raising Total of £19M ($24.5M) and Welcomes Sound Bioventures as New Investor". Oxford....
- [2] Genmab A/S. (4/3/24). "Press Release: Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio". Copenhagen & Seattle, WA....
- [3] Firefly Bio, Inc.. (2/15/24). "Press Release: Firefly Bio Debuts with $94 Million Series A Financing". South San Francisco, CA....
- [4] BioNTech SE. (1/31/24). "Press Release: BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305". Mainz & Shanghai....
- [5] Prism BioLab Co., Ldt.. (1/24/24). "Press Release: Prism BioLab Raises 1.5 Billion Yen in Series C Fundraising to Advance Technologies and Programs Targeting Protein-protein Interactions". Tokyo....
- [6] BioNTech SE. (1/22/24). "Press Release: BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer". Mainz & Shanghai....
- [7] BioNTech SE. (1/9/24). "Press Release: BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference". Mainz....
- [8] Human Immunology Biosciences, Inc. (HI-Bio). (1/4/24). "Press Release: HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases". South San Francisco, CA....
- [9] Menarini Group. (1/4/24). "Press Release: Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications". Florence & New York, NY....
- [10] MediLink Therapeutics (Suzhou) Co., Ltd.. (1/2/24). "Press Release: MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to Develop Next-generation Antibody Drug Conjugate in Oncology". Suzhou....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top